Chengdu Olymvax Stock Hits Day Low of CNY 35.60 Amid Price Pressure

Chengdu Olymvax Biopharmaceuticals, Inc. experienced significant volatility on July 13, 2026, with the stock hitting an intraday low of CNY 35.60. The company saw a notable decline of 19.56% for the day, contrasting sharply with the China Shanghai Composite's decrease of 2.06%. Over the past week, the stock has dropped 17.69%, while its monthly performance remains slightly positive at 1.36%. Despite the recent downturn, Chengdu Olymvax has demonstrated strong performance metrics over the longer term. The company reported a remarkable 108.04% increase in stock value over the past year, significantly outperforming the China Shanghai Composite, which rose by 11.5%. Year-to-date, the stock has gained 40.77%, further highlighting its resilience in the market. Financially, the company has shown robust growth, with net sales increasing by 25.38%. Key performance indicators such as a return on capital employed (ROCE) of 6.86% and an impressive interest coverage ratio of 1,289.5 underscore its financial health. As a large-cap player in the pharmaceuticals and biotechnology sector, Chengdu Olymvax continues to navigate a dynamic market landscape.